Attached files

file filename
EX-99.1 - RAPTOR PHARMACEUTICAL CORP PRESS RELEASE DATED SEPTEMBER 12, 2013 - Raptor Pharmaceutical Corprptp_pr091213_euprocysapprvl.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2013
____________________
RAPTOR PHARMACEUTICAL CORP.
(Exact name of registrant as specified in its charter)


Delaware
(State or other jurisdiction of incorporation)
 
 000-25571
(Commission File Number)
 
86-0883978
(IRS Employer Identification Number)

5 Hamilton Landing, Suite 160
Novato, California 94949
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (415) 408-6200
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





 
Item 8.01                          Other Events.
On September 12, 2013, Raptor Pharmaceutical Corp. issued a press release announcing that the European Commission has approved PROCYSBI® gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate) as an orphan medicinal product for the treatment of proven nephropathic cystinosis for marketing in the European Union.  A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01                          Financial Statements and Exhibits.
(d)            Exhibits.
 
Exhibit No.
 
Exhibit Description
99.1
Press release dated September 12, 2013.





 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:  September 12, 2013 RAPTOR PHARMACEUTICAL CORP.


By:             /s/ Georgia Erbez
Name:  Georgia Erbez
Title: Chief Financial Officer, Secretary and Treasurer







 

Exhibit Index

 
Exhibit No.
 
Exhibit Description
99.1
Press release dated September 12, 2013.